These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

808 related items for PubMed ID: 33309574

  • 21. Atrial Fibrillation as a Prognostic Factor for All-Cause Mortality in Patients With Transthyretin Amyloid Cardiomyopathy.
    Witteles R, Jefferies JL, Kapa S, Cappelli F, Sultan MB, Gundapaneni B, Davis MK, Garcia-Pavia P.
    JACC CardioOncol; 2024 Aug; 6(4):592-598. PubMed ID: 39239341
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Reduction in 99mTc-DPD myocardial uptake with therapy of ATTR cardiomyopathy.
    Rettl R, Calabretta R, Duca F, Binder C, Kronberger C, Willixhofer R, Poledniczek M, Donà C, Nitsche C, Beitzke D, Loewe C, Auer-Grumbach M, Bonderman D, Kastl S, Hengstenberg C, Badr Eslam R, Kastner J, Bergler-Klein J, Hacker M, Kammerlander A.
    Amyloid; 2024 Mar; 31(1):42-51. PubMed ID: 37599395
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis.
    Benbrahim M, Norman K, Sanchorawala V, Siddiqi OK, Hughes D.
    J Cardiovasc Pharmacol; 2021 May 01; 77(5):544-548. PubMed ID: 33657048
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Modeling of Survival and Frequency of Cardiovascular-Related Hospitalization in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis.
    Vong C, Boucher M, Riley S, Harnisch LO.
    Am J Cardiovasc Drugs; 2021 Sep 01; 21(5):535-543. PubMed ID: 33770392
    [Abstract] [Full Text] [Related]

  • 33. Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey.
    Nativi-Nicolau J, Siu A, Dispenzieri A, Maurer MS, Rapezzi C, Kristen AV, Garcia-Pavia P, LoRusso S, Waddington-Cruz M, Lairez O, Witteles R, Chapman D, Amass L, Grogan M, THAOS Investigators.
    JACC CardioOncol; 2021 Oct 01; 3(4):537-546. PubMed ID: 34729526
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Clinical, electrocardiographic, and echocardiographic parameters associated with the development of pacing and implantable cardioverter-defibrillator indication in patients with transthyretin amyloid cardiomyopathy.
    Kawahara Y, Kanazawa H, Takashio S, Tsuruta Y, Sumi H, Kiyama T, Kaneko S, Ito M, Hoshiyama T, Hirakawa K, Ishii M, Tabata N, Yamanaga K, Fujisue K, Hanatani S, Sueta D, Arima Y, Araki S, Usuku H, Nakamura T, Yamamoto E, Soejima H, Matsushita K, Kawano H, Tsujita K.
    Europace; 2023 May 19; 25(5):. PubMed ID: 37099643
    [Abstract] [Full Text] [Related]

  • 36. Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).
    Maurer MS, Elliott P, Merlini G, Shah SJ, Cruz MW, Flynn A, Gundapaneni B, Hahn C, Riley S, Schwartz J, Sultan MB, Rapezzi C, ATTR-ACT Study Investigators.
    Circ Heart Fail; 2017 Jun 19; 10(6):. PubMed ID: 28611125
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. [Neurological manifestations of ATTR amyloidosis].
    Pernice HF, Hahn K.
    Inn Med (Heidelb); 2023 Sep 19; 64(9):848-854. PubMed ID: 37555967
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Relationship of binding-site occupancy, transthyretin stabilisation and disease modification in patients with tafamidis-treated transthyretin amyloid cardiomyopathy.
    Tess DA, Maurer TS, Li Z, Bulawa C, Fleming J, Moody AT.
    Amyloid; 2023 Jun 19; 30(2):208-219. PubMed ID: 36399070
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 41.